2021
WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway
Guo E, Xiao R, Wu Y, Lu F, Liu C, Yang B, Li X, Fu Y, Wang Z, Li Y, Huang Y, Li F, Wu X, You L, Qin T, Lu Y, Huang X, Ma D, Mills G, Sun C, Chen G. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. Journal Of Experimental Medicine 2021, 219: e20210789. PMID: 34825915, PMCID: PMC8628262, DOI: 10.1084/jem.20210789.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCD8-Positive T-LymphocytesCell Cycle ProteinsCell Line, TumorEndogenous RetrovirusesEnzyme InhibitorsFemaleGene Expression Regulation, NeoplasticHCT116 CellsHumansImmune Checkpoint InhibitorsMice, Inbred BALB CMice, Inbred C57BLMice, Inbred NODMice, SCIDNeoplasms, ExperimentalProtein-Tyrosine KinasesPyrazolesPyrimidinonesRNA, Double-StrandedSignal TransductionTumor BurdenConceptsImmune checkpoint blockadeAnti-tumor immunityEndogenous retroviral elementsWEE1 inhibitionCheckpoint blockadeCD8+ T cell-dependent mannerSensitivity to immune checkpoint blockadeResponse to immune checkpoint blockadeAnti-tumor T cellsCombination of WEE1 inhibitorT cell-dependent mannerPathway-targeted therapiesMultiple tumor modelsPopulation of patientsEmergence of resistanceDown-regulating FoxM1Viral defense pathwaysPD-L1Tumor regressionCombination therapyTargeted therapyCombination partnerT cellsPatient selectionWEE1 inhibitor
2020
Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma
Gong Y, Fan Z, Luo G, Huang Q, Qian Y, Cheng H, Jin K, Ni Q, Yu X, Liu C. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Pancreatology 2020, 20: 716-721. PMID: 32249060, DOI: 10.1016/j.pan.2020.02.016.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalFemaleHumansMaleMiddle AgedPancreatic NeoplasmsPancreatitisRisk FactorsSurvival AnalysisConceptsHistory of APPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma patientsLog-rank testAcute pancreatitisSurgical resectionDuctal adenocarcinomaPoor survivalHazard ratioHistory of acute pancreatitisDiagnosis of pancreatic ductal adenocarcinomaAssociated with poor survivalIndependent survival predictorMultivariable-adjusted hazard ratiosKaplan-Meier methodRetrospective cohort studyCox proportional hazards modelsProportional hazards modelOverall survivalRemote historyClinical characteristicsCohort studyMultivariate analysisRisk factors
2015
Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer
Liu Z, Luo G, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology 2015, 15: 253-258. PMID: 25921232, DOI: 10.1016/j.pan.2015.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDeoxycytidineFemaleHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatectomyPancreatic NeoplasmsRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsAdjuvant chemoradiotherapyLymph node statusNode statusPancreatic cancerPancreatic adenocarcinomaDifferent lymph node statusCurative R0 resectionEffect of chemoradiotherapyImproved median OSLN-negative diseaseLN-positive diseaseRole of lymphOverall median survivalMedian OSAdjuvant therapyR0 resectionMedian survivalPositive diseaseNegative diseaseChemoradiotherapyPatientsMultivariate analysisDiseaseLymphAdenocarcinoma
2014
Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy
Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q, Yu X. Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy. Annals Of Surgical Oncology 2014, 22: 670-676. PMID: 25155401, DOI: 10.1245/s10434-014-4021-y.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansLymphocytesMaleMiddle AgedNeutrophilsPancreatic NeoplasmsPrognosisRetrospective StudiesSurvival AnalysisConceptsNeutrophil-to-lymphocyte ratioBaseline neutrophil-to-lymphocyte ratioAdvanced pancreatic cancerNLR changeOverall survivalPancreatic cancerPrognostic roleMultivariate analysisPredictor of overall survivalSerum CA19-9 levelsPredictor of poor survivalAdvanced pancreatic adenocarcinomaCA19-9 levelsSerum albumin levelCox proportional hazards modelsProportional hazards modelPostchemotherapy changesClinicopathological predictorsDistant metastasisPrognostic factorsPancreatic adenocarcinomaClinicopathological characteristicsAlbumin levelsPoor survivalPredicting survival
2012
Management of a Malignant Case of Solid Pseudopapillary Tumor of Pancreas
Ji S, Xu J, Zhang B, Xu Y, Liu C, Long J, Ni Q, Yu X. Management of a Malignant Case of Solid Pseudopapillary Tumor of Pancreas. Pancreas 2012, 41: 1336-1340. PMID: 22699200, DOI: 10.1097/mpa.0b013e31824d52c7.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, PapillaryFemaleFloxuridineHumansLiver NeoplasmsMiddle AgedOrganoplatinum CompoundsOxaliplatinPancreatectomyPancreatic NeoplasmsPortal VeinPrognosisThrombosisTreatment OutcomeConceptsSolid pseudopapillary tumorMalignant SPTPseudopapillary tumorCase of solid pseudopapillary tumorCases of metastasisUnresectable tumorsExcellent prognosisMalignant potentialClinicopathological featuresSurgical removalMalignant casesTumorYoung femalesPancreasRadiotherapyChemotherapyMetastasisNeoplasmsPrognosisRecurrencePatientsCases